IGM Biosciences (Formerly Palingen)

About IGM Biosciences (Formerly Palingen)

IGM Biosciences, Inc. is a clinical-stage biotechnology company focused on engineering and developing a new class of medicines based on Immunoglobulin M (IgM) antibodies. The entity was first established in 1993 as Palingenesis, Inc., and later rebranded, shifting its focus exclusively to the development of engineered IgM antibodies. A significant milestone was its initial public offering on the Nasdaq (IGMS) on September 18, 2019, which raised substantial capital to advance its technology platform.

The company's business model is centered on research and development, funded primarily through strategic collaborations, licensing agreements, and milestone payments from pharmaceutical partners. As a clinical-stage firm, it does not yet have approved products for sale. A key partnership includes an exclusive worldwide collaboration with Sanofi to create and develop IgM antibody agonists for oncology, immunology, and inflammation targets, which involved a $150 million upfront payment. However, in recent strategic shifts, the company has halted development on some programs to prioritize others and manage its cash runway.

IGM's proprietary technology platform is designed to overcome historical manufacturing and engineering challenges associated with IgM antibodies. Unlike traditional Immunoglobulin G (IgG) antibodies that have two binding sites, IgM antibodies possess ten, which can result in stronger binding (higher avidity) to cell surface targets. This structural difference is intended to create more effective therapies. The company's pipeline has explored treatments for cancer, autoimmune diseases, and infectious diseases. Key product candidates have included Aplitabart (for colorectal cancer), Imvotamab (for autoimmune diseases like rheumatoid arthritis and lupus), and IGM-2644 (for autoimmune diseases). Following a strategic pivot in late 2024, the company decided to focus its resources on developing T cell engaging IgM antibodies for autoimmune diseases, appointing Dr. Mary Beth Harler as the new CEO to lead this effort.